Hemostatic Factors: Lipid Theory: Prevention. Diabetes Mellitus: Dietary Management, Fatty Acids: Omega-6 Polyunsaturated. Lactation: Dietary Requirements. Pregnancy: Nutrient Requirements; Safe Diet for

Pregnancy.

## **Further Reading**

- Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, and Deadman NM (1989) Effect of changes in fat fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2:
- Calon F. Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P. Triller A. Salem N Ir, Ashe KH, Frautschy SA, and Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43: 633-645.
- de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, and Delaye J (1994) Mediterranean alpha-linolenic acid rich-diet in the secondary prevention of coronary heart disease. Lancet 343: 1454-1459.
- Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, and Mehrabian M (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New England Journal of Medicine 350: 29-37.
- GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354: 447-455.
- Kang JX, Wang J, Wu L, and Kang ZB (2004) Fat-1 mice convert n-6 to n-3 fatty acids. Nature 427: 504.
- Maes M, Smith R, Christophe A, Cosyns P, Desynder R, and Meltzer H (1996) Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. Journal of Affective Disorders 38(1): 35-46.
- Mechanisms of Action of LCPUFA (2003) Effects on infant growth and neurodevelopment. Proceedings of a conference held in Arlington, Virginia, May 14-15, 2002. Journal of Pediatrics 143(supplement 4): S1-S109.
- Simopoulos AP (2001) N-3 fatty acids and human health: defining strategies for public policy. Lipids 36: S83-S89.
- Simopoulos AP (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of American College of Nutrition 21: 494-505.
- Simopoulos AP and Cleland LG (eds.) (2003) Omega-6/Omega-3 Essential Fatty Acid Ratio: The Scientific Evidence. World Review of Nutrition and Dietetics, vol. 92 Basel: Karger.
- Simopoulos AP, Leaf A, and Salem N Jr (1999) Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Annals of Nutrition and Metabolism 43: 127-130.
- Simopoulos AP and Nestel PJ (eds.) (1997) Genetic Variation and Dietary Response. World Review of Nutrition and Dietetics, vol. 80, Basel: Karger.
- Simopoulos AP and Robinson J (1999) In The Omega Diet. The Lifesaving Nutritional Program Based on the Diet of the Island of Crete. New York: Harper Collins.
- Simopoulos AP and Visioli F (eds.) (2000) Mediterranean Diets. World Review of Nutrition and Dietetics, vol. 87. Basel: Karger. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, and Berry EM (2002) Effect of an Indo-

Mediterranean diet on progression of coronary artery disease in

high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet 360(9344): 1455-1461. Yehuda S (2003) Omega-6/omega-3 ratio and brain-related functions. World Review of Nutrition and Dietetics 92: 37-56.

# Omega-6 Polyunsaturated

J M Hodgson and T A Mori, University of Western Australia, Perth, WA, Australia

M L Wahlqvist, Monash University, Victoria, VIC, Australia

© 2005 Elsevier Ltd. All rights reserved.

# Structure, Function, and Nutritional Requirements

Omega-6 (n-6) fatty acids are a class of polyunsaturated fatty acids (PUFA). They have two or more cis double bonds, with the position of the first double bond six carbon atoms from the methyl end of the molecule. The general formula of n-6 fatty acids is  $CH_3(CH_2)_4(CH = CHCH_2)_x(CH_2)_yCOOH$  [where x = 2-5]. Linoleic acid (cis-9, cis-12-octadecadienoic acid, 18:2n-6, LA) and  $\alpha$ -linolenic acid (cis-9. cis-12, cis-15-octadecatrienoic acid, 18:3n-3, ALA) are the precursor fatty acids of the n-6 and omega-3 (n-3) fatty acids, respectively. These two fatty acids cannot be made by mammals and are therefore termed essential fatty acids (EFA). In addition, mammals are unable to interconvert LA and ALA, or any of the n-6 and n-3 fatty acids, because mammalian tissues do not contain the necessary desaturase enzyme. Plant tissues and plant oils tend to be rich sources of LA. ALA is also present in plant sources such as green vegetables, flaxseed, canola, and some nuts. Once consumed in the diet, LA can be converted via chain elongation and desaturation to  $\gamma$ -linolenic acid (GLA, 18:3n-6), dihomo- $\gamma$ -linolenic acid (DGLA, 20:3n-6), and arachidonic acid (AA, 20:4n-6) (Figure 1). The same enzymes involved in elongation and desaturation of the n-6 fatty acids are common to the n-3 series of fatty acids (Figure 1). Thus, ALA can be converted to eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). EPA and DHA are found in relatively high proportions in marine oils.

The n-6 and n-3 fatty acids are metabolically and functionally distinct and often have important opposing physiological functions. Indeed, the balance of EFA is important for good health and normal development. Historically, human beings evolved on a diet in which the ratio of n-6 to n-3 fatty acids was about 1:1. In contrast, Western diets have a ratio of




Figure 1 Essential fatty acid metabolism.

approximately 15:1. Evidence for this change in diet through history comes from studies on the evolutionary aspects of diet, modern-day hunter-gatherers, and traditional diets. Modern agriculture has led to a substantial increase in n-6 fatty acids at the expense of n-3 fatty acids, which has resulted in excessive consumption of n-6 fatty acids by humans.

The n-6 EFAs have two main functions. First, they act as structural components of membranes forming the basis of the phospholipid component of the lipid bilayer of plasma membranes in every cell in the body, thus providing a membrane impermeable to most water-soluble molecules. The length and degree of saturation of the fatty acids determine how the phospholipid molecules pack together and consequently affect membrane fluidity, signal transduction, and the expression of cellular receptors. The second role of n-6 fatty acids is as precursors to the eicosanoids (Figure 1). The eicosanoids are a family of 'hormone-like' compounds including prostaglandins (PGs), leukotrienes (LTs), hydroxy- (HETEs), dihydroxy- (DiHETEs), and epoxy- (EETs) fatty acids. Eicosanoids, however, are distinct from most hormones in that they act locally, near their sites of synthesis, and they are catabolized extremely rapidly. Thus, they are considered to be locally acting hormones. The eicosanoids modulate renal and pulmonary function, vascular tone, and inflammatory responses. The enzymes involved in AA metabolism include the cyclooxygenases and lipoxygenases, which yield the 2-series PGs and 4-series LTs, respectively. Lipoxygenase also utilizes AA for the formation of the HETEs. A third pathway for the utilization of AA involves the cytochrome P-450 enzymes found in the liver, kidney, lung, intestines, heart, small blood vessels, and white blood cells. AA metabolized via cytochrome P-450 yields EETs, DiHETEs, as well as HETEs. The cytochrome P-450 metabolites play an important role as paracrine factors and second messengers in the regulation of pulmonary, cardiac, renal, and vascular function and modulate inflammatory and growth responses.

# **Endothelial Function, Atherosclerosis, and Cardiovascular Disease**

Differences in n-6 fatty acid intake have the potential to influence several chronic diseases and disorders. This article will focus on the effects of n-6 fatty acids on cardiovascular disease and atherosclerosis.

The vascular endothelium is the most important organ controlling vascular function and consists of a single layer of epithelial cells lining blood vessels. Its primary function is to regulate vascular tone, but it plays a critical role in modulating coagulation and fibrinolysis, inflammation, smooth muscle cell proliferation, and macrophage function. Many of these functions are regulated through the release of various mediators including eicosanoids. There is multiple and close interaction of the endothelial cells with circulating cells, smooth muscle cells, and macrophages. There is also evidence that endothelial dysfunction precedes clinically apparent atherosclerosis.

Atherosclerosis is an inflammatory disease involving multiple cellular and molecular responses that lead to an alteration in vascular function and structure, and the development and progression of cardiovascular disease. Atherosclerosis is characterized by degenerative changes, deposition of cholesterol, proliferation of smooth muscle cells, involvement of a range of circulating proinflammatory cell types, and fibrosis. Resulting atheromatous plaques cause narrowing of arteries and increase the likelihood of thrombosis and occlusion. When this process occurs in the coronary arteries, the outcome is myocardial infarction and with possible death.

# Eicosanoids: Relevance to Endothelial Function, Thrombosis, Inflammation, and Atherosclerosis

In general, the eicosanoids derived from AA have potent prothrombotic and proinflammatory activity. In contrast, the eicosanoids derived from EPA have reduced biological activity and are less prothrombotic and proinflammatory. Eicosanoid production is generally tightly controlled through homeostatic mechanisms. However, eicosanoid production can be significantly altered in situations in which endothelial dysfunction, atherosclerosis and plaque rupture, or various thrombotic or inflammatory conditions are present.

# **Prostaglandins and Leukotrienes**

Prostaglandins have a central role in the regulation of platelet aggregation and vascular tone. In this regard, two of the major prostaglandins derived from AA are thromboxane A<sub>2</sub>, produced in platelets, and prostacyclin I<sub>2</sub>, produced in endothelial cells. Thromboxane A<sub>2</sub> promotes platelet aggregation and blood vessel constriction, while prostacyclin I<sub>2</sub> has the opposite effects. An increase in availability of EPA can decrease platelet thromboxane A<sub>2</sub> and increase thromboxane A<sub>3</sub>, the latter having

considerably less physiological activity. EPA supplementation also stimulates formation of prostacyclin  $I_3$ , while prostacyclin  $I_2$  is unaffected. Prostacyclin  $I_3$  and prostacyclin  $I_2$  are equipotent in their biological activity. The net result following intake of n-3 fatty acids is a shift in the thromboxane/prostacyclin balance toward a reduced prothrombotic state.

Leukotriene B<sub>4</sub> is a potent inflammatory mediator produced by neutrophils from 20:4n-6 at the site of injury. Leukotriene B<sub>4</sub> is also a powerful chemotactic factor responsible for attracting neutrophils to the site of injury. Leukotriene B<sub>5</sub>, which is produced from EPA, has significantly lower biological activity. Therefore an increased availability of EPA has the potential to reduce inflammation.

### **Fatty Acid Intake and Eicosanoids**

The proportional concentration of the eicosanoid precursor fatty acids both circulating and in tissues depends on dietary intake. DGLA and AA can be obtained from animal meat and fat, and by desaturation and chain elongation of LA. The major dietary source of EPA is fish. EPA can also be obtained indirectly from ALA, although desaturation and chain elongation of ALA appears to be a less important pathway in humans.

Only the free form of the fatty acid precursors of eicosanoids can be utilized by the enzymes for conversion to the biologically active metabolites. However, the amount of precursor free fatty acid in the cytoplasm and circulating is usually low and so too is basal eicosanoid formation. Furthermore, basal eicosanoid formation may depend on dietary and adipose tissue fatty acid composition. The amount of eicosanoid precursor free fatty acids is controlled to a large extent by incorporation and release from cellular phospholipids. Which eicosanoids are produced during stimulated synthesis may depend on membrane fatty acid composition as well as the cell type involved. Dietary fatty acid composition, therefore, has the potential to effect basal and stimulated synthesis of eicosanoids and influence endothelial function and thrombotic and inflammatory responses.

# n-6 Fatty Acids and Risk of Cardiovascular Disease

Evidence that differences in n-6 fatty acid intake can influence cardiovascular disease risk derives from several sources. Population studies may provide useful data for establishing optimal intakes of n-6 fatty acids. However, valuable information on the potential mechanisms and effects of these fatty acids is

derived from studies focusing on their impact on thrombosis, inflammation, endothelial function, and other cardiovascular risk factors.

### **Cardiovascular Disease: Population Studies**

The incidence of cardiovascular disease within populations with either very high or very low intakes of n-6 fatty acids may provide some indication for optimal intakes of n-6 fatty acids. Within populations with low n-6 fatty acid intakes (\le 3\%) there would appear to be a benefit of having a higher n-6 fatty acid intake on cardiovascular disease risk reduction. These observations suggest that very low n-6 fatty acid intakes increase the risk for cardiovascular disease. The presence of EFA deficiency in a significant proportion of such populations may explain the increased risk. Several populations, including the Israelis, Taiwanese, and !Kung bushmen in the African Kalahari desert, have high to very high intakes of n-6 fatty acids. The contribution of n-6 fatty acids to total energy intake is about 10% in the Israelis and Taiwanese and about 30% in the !Kung bushmen. Rates of cardiovascular disease are low in the Taiwanese, where dietary n-6 fatty acids are obtained mainly from soybean oil, and estimated to be very low in the !Kung bushmen, where dietary n-6 fatty acids were obtained mainly from the monongo fruit and nut. In the Taiwanese, the soybean oil is refined but is accompanied by a diet rich in antioxidant polyphenols, notably from tea, fruits, and vegetables. In the !Kung bushmen the oil is unrefined and is therefore likely to contain a range of phytochemicals. There is, however, a high prevalence of cardiovascular disease in the Israeli population, where n-6 PUFAs are obtained largely from refined sources. These observations suggest that a high n-6 fatty acid intake can be compatible with low risk of cardiovascular disease, but the dietary context may be very important. Given that n-6 fatty acids are susceptible to lipid peroxidation, high n-6 fatty acid intake may increase risk for cardiovascular disease when consumed against a background diet low in antioxi-The potential impact on dants. metabolism remains uncertain.

Several factors may need to be considered in the interpretation of the results of population studies. First, the effect of LA on atherosclerosis and cardiovascular disease may depend on the background intake in the population being studied. Second, any relationships observed may be confounded by intake of other foods from which LA derives. Third, LA may have differential effects on aspects of the aetiology of cardiovascular disease, including

endothelial function, thrombosis, arrhythmia, and atherosclerosis.

#### **Thrombosis**

Dietary fatty acids influence thrombosis by altering the activity and function of endothelial cells, platelets, and other circulating cells-effects that can be mediated, in part, by alterations in eicosanoid metabolism. Replacement of dietary saturated fatty acids with unsaturated fatty acids, including n-6 fatty acids, generally lowers the risk of thrombosis and cardiovascular disease. Furthermore, studies have shown that an increase in n-3 fatty acid intake can increase vasodilation, attenuate platelet aggregation, and alter circulating concentrations of factors involved in coagulation and fibrinolysis. The net effect of increasing n-3 fatty acid intake is a tendency toward reduced risk for thrombosis. These findings are supported by population studies demonstrating that n-3 fatty acids may reduce the risk of thrombosis. It remains uncertain whether the major factor influencing these functions is the absolute increase in n-3 fatty acids or the relative proportions of n-6 and n-3 fatty acids in the diet and cell membranes. There is evidence, however, that increased n-3 fatty acid intake may be more beneficial in populations consuming relatively small quantities of fish, which includes many Western populations.

Much of the evidence for a potential impact of n-6 fatty acids on thrombosis derives from research on platelet function. The role of platelets in thrombosis is established and the influence of fatty acid intake on platelet function has been assessed in many studies. Platelets play a part in thrombosis by adhering to, and aggregating at, the site of injury. Platelet reactivity and increased platelet activation may increase the risk of thrombosis. In vitro and in vivo studies assessing effects of n-6 fatty acids on platelet aggregation are inconsistent. To date there is little evidence that a high n-6 fatty acid diet in humans decreases platelet aggregation and some studies are suggestive of increased aggregation with high n-6 fatty acid diets, primarily in the form of LA. The effects of AA on platelet aggregation are also not clear. One of the main difficulties in interpreting these studies is the unresolved issue as to how the in vitro aggregation test reflects platelet function in vivo.

### Inflammation

Conditions of increased inflammation, such as inflammatory arthritis, dermatological conditions such as psoriasis and atopic dermatitis, chronic

inflammatory bowel disease, autoimmune diseases, and bronchial asthma, appear to be beneficially influenced by n-3 fatty acids but not by n-6 fatty acids.

Whether or not increased intake of n-6 fatty acids can exacerbate inflammation via increased production of proinflammatory eicosanoids remains uncertain. Results of in vitro studies and intervention studies in humans are generally consistent with this theoretical potential of n-6 fatty acids to enhance inflammation, at least in comparison to n-3 fatty acids and probably n-9 monounsaturated fatty acids. The importance of absolute and relative intakes of n-6 fatty acids to inflammatory processes also remains unclear. The effects of changes in n-6 fatty acid intake on inflammatory processes may depend on the background dietary fatty acid intake, as well as proportional and absolute intake of n-3 fatty acids.

#### **Cholesterol and Lipoproteins**

The major classes of circulating lipoproteins in human plasma are chylomicrons, very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). High fasting plasma concentrations of LDL cholesterol and triglycerides—predominantly circulating part of VLDL—and low plasma concentrations of HDL cholesterol are associated with increased risk of cardiovascular disease. Dietary fatty acids can influence lipoprotein metabolism and therefore have the potential to influence atherosclerosis and cardiovascular disease risk. Most studies examining the effects of n-6 PUFAs on cholesterol metabolism have focused on LA, the major dietary n-6 fatty acid.

It is now established that LDL cholesterol lowering reduces the risk of cardiovascular disease. In the fasting state LDL is the major cholesterol carrying lipoprotein in human plasma. The mechanisms through which raised plasma LDL cholesterol concentrations increase cardiovascular disease risk are not entirely understood but oxidative modification of LDL is thought to be involved. An increase in LA intake results in a lowering of plasma LDL cholesterol concentrations and therefore has the potential to reduce cardiovascular disease risk. These effects may not be linear over the entire range of LA intake and most of the benefits appear to be gained by moving from lower (<2% of energy) to moderate  $(\sim 4-5\%$  of energy) intakes. In addition, it is worthy of note that the effects of dietary n-6 PUFAs are less than half that of lowering dietary saturated fatty acids. Therefore, if total fat intake is maintained,

the LDL cholesterol lowering effects of increasing n-6 PUFA intake are greatly enhanced if saturated fatty acid intake is decreased.

HDL cholesterol is inversely associated with cardiovascular disease risk. The mechanism by which HDL reduces cardiovascular disease risk may involve reverse cholesterol transport and reductions in cholesterol accumulation in the arterial wall. Intakes of LA within the normal ranges of intakes in most populations do not appear to alter HDL cholesterol concentrations. However, very high intakes-above 12% of energy-can lower HDL cholesterol concentrations.

#### **Oxidative Stress**

Several lines of evidence suggest that oxidatively modified LDL plays an important role in the development of atherosclerosis. Oxidative modification of LDL involves peroxidation of PUFAs. LDL particles enriched in PUFAs have been shown to be more susceptive to oxidative modification compared to LDL particles rich in monounsaturated fatty acids. Others have also suggested that a diet high in PUFAs may overwhelm the antioxidant defenses of cells. In particular, studies have shown that LA-enriched LDL is more prone to in vitro oxidation than oleic acid-enriched LDL. Concern also remains with respect to the potential for increased lipid peroxidation following n-3 fatty acids. To date, however, the data in vivo are inconclusive, with observations of increased, unchanged, and decreased lipid peroxidation. The most plausible explanation relates to differences in the methodologies employed to assess lipid peroxidation. Much of the literature relating to PUFAs and lipid peroxidation is based on indirect and nonspecific assays, including measurement of LDL oxidative susceptibility, which relies on the isolation of LDL from plasma. In this regard, the recent discovery of F2-isoprostanes, which are nonenzymatic prostaglandin-like products of free radical peroxidation of arachidonic acid, has allowed for the direct assessment of in vivo lipid peroxidation. There is now good evidence that quantitation of F<sub>2</sub>-isoprostanes provides a reliable measure of in vivo oxidative stress. Using measurement of F<sub>2</sub>isoprostanes, recent data have demonstrated that n-3 fatty acids decrease oxidative stress. It has also been suggested that the concentration of PUFAs may be a more important factor affecting lipid peroxidation than the degree of unsaturation. Further research using better markers of lipid peroxidation is required before definitive statements can be made relating to the effect of n-6 fatty acids, and indeed PUFAs in general, on oxidative stress.

#### **Blood Pressure**

The possible effects of dietary fatty acids on blood pressure have been explored in population studies and dietary intervention trials. With the exception of studies comparing vegetarian and nonvegetarian populations, from which there is a suggestion of a blood pressure lowering effect of diets high in PUFAs, including LA, and lower in saturated fatty acids, the results of most within- and between-population studies have generally not found significant associations. The results of intervention studies suggest that n-6 fatty acids, LA in particular, may be responsible for a small blood pressure lowering effect. However, these studies are also inconsistent, with several failing to find a significant blood pressure lowering effect.

#### **Conclusions**

Diets low in n-6 fatty acids, principally LA, appear to be associated with an increased risk of cardiovascular disease. The results of studies examining the effects of LA on risk factors for atherosclerosis and cardiovascular disease are consistent with this observation. An increase in n-6 PUFA intake from a low to a moderate intake level, in conjunction with decreases in total and saturated fat intake, may beneficially influence lipoprotein metabolism, lower blood pressure, and reduce cardiovascular disease risk. Observations in populations with high n-6 PUFA intake indicate that high intakes of n-6 fatty acids (>10%) can occur together with low rates of cardiovascular disease and possibly also cancer. However, where antioxidant composition of the diet is low, there is the potential for increased risk of cardiovascular disease. An increased susceptibility of PUFAs to oxidative damage, particularly in the presence of low concentrations of protective antioxidants, may be an important factor involved. The source of n-6 PUFAs in the diet, refined versus unrefined, and the composition of the background diet may therefore be important determinants of whether high n-6 fatty acid intake increases or decreases risk of cardiovascular disease. In addition, the proportion of n-6 to n-3 fatty acids in the diet may also play an important role in determining cardiovascular risk.

The available evidence suggests that n-6 fatty acid-derived eicosanoids are generally proinflammatory and prothrombotic. In contrast, eicosanoids derived from n-3 fatty acids have attenuated biological activity on cardiovascular risk factors. The effects of altering n-6 PUFA intake, in conjunction with changes in other polyunsaturated fatty acids, as

well as other classes of fatty acids, on endothelial function, thrombosis, and inflammation are not understood. The relative proportion of all the classes of fatty acids in the diet may well be more important and relevant to cardiovascular risk reduction than any single class of fatty acids. Clearly such research warrants further investigation.

See also: Cholesterol: Sources, Absorption, Function and Metabolism; Factors Determining Blood Levels. Coronary Heart Disease: Lipid Theory. Fatty Acids: Metabolism; Monounsaturated; Omega-3 Polyunsaturated; Saturated; Trans Fatty Acids. Fish. Lipoproteins. Prostaglandins and Leukotrienes.

### **Further Reading**

Grundy SM (1996) Dietary fat. In: Ziegler EE and Filer LJ Jr. (eds.) Present knowledge in Nutrition, 7th edn., pp. 44-57. Washington, DC: ILSI Press.

Hodgson JM, Wahlqvist ML, Boxall JA, and Balazs NDH (1993) Can linoleic acid contribute to coronary artery disease? *American Journal of Clinical Nutrition* 58: 228-234.

Hodgson JM, Wahlqvist ML, and Hsu-Hage B (1995) Diet, hyperlipidaemia and cardiovascular disease. Asia Pacific Journal of Clinical Nutrition 4: 304-313.

Hornsrtra G, Barth CA, Galli C et al. (1998) Functional food science and the cardiovascular system. British Journal of Nutrition 80(supplement 1): S113-S146.

Horrobin DF (ed.) (1990) Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York: Wiley-Liss.

Jones GP (1997) Fats. In: Wahlqvist ML (ed.) Food and Nutrition, Australia, Asia and the Pacific, pp. 205-214. Sydney: Allen & Unwin.

Jones PJH and Kubow S (1999) Lipids, sterols and their metabolism. In: Shils ME, Olson JA, Shike M, and Ross AC (eds.) Modern Nutrition in Health and Disease, 9th edn., pp. 67-94. Baltimore: Williams & Wilkins.

Knapp HR (1997) Dietary fatty acids in human thrombosis and hemostasis. American Journal of Clinical Nutrition 65(supplement 5): 16875–1698S.

Lyu LC, Shieh MJ, Posner BM et al. (1994) Relationship between dietary intake, lipoproteins and apolipoproteins in Taipei and Framingham. American Journal of Clinical Nutrition 60: 765-774.

Mensink R and Connor W (eds.) (1996) Nutrition. Current Opinion in Lipidology 7: 1-53.

National Health and Medical Research Council (1992) The role of polyunsaturated fats in the Australian diet: Report of the NHMRC working party. Canberra: Australian Government Publishing Service.

Salem N, Simopoulos AP, Galli, Lagarde M, and Knapp HR (eds.) (1996) Fatty acids and lipids from cell biology to human disease: Proceedings of the 2nd International Congress of the International Society for the Study of Fatty Acids and Lipids. *Lipids* 31 (supplement).

Truswell AS (1977) Diet and nutrition of hunter gatherers. Ciba Foundation Symposium, 213-221.

Yam D, Eliraz A, and Berry EM (1996) Diet and disease—The Israeli paradox: Possible dangers of a high omega-6 polyunsaturated fatty acid diet. *Israeli Journal of Medical Sciences* 32: 1134–1143.

# CONTENTS

# VOLUME 1

A	
ACIDS see ELECTROLYTES: Acid-Base Balance	
ADIPOSE TISSUE G Frühbeck and J Gómez-Ambrosi	-
ADOLESCENTS	
Nutritional Requirements C H S Ruxton and J Fiore	15
Nutritional Problems C Lo	26
AGING P Hyland and Y Barnett	40
ALCOHOL	
Absorption, Metabolism and Physiological Effects R Rajendram, R Hunter, V Preedy and T Peters	48
Disease Risk and Beneficial Effects M Grønbæk	57
Effects of Consumption on Diet and Nutritional Status C H Halsted	62
ALUMINUM N D Priest	69
AMINO ACIDS	
Chemistry and Classification P W Emery	70
Metabolism P W Emery	84
Specific Functions M C G van de Poll, Y C Luiking, C H C Dejong and P B Soeters	92
ANEMIA	
Iron-Deficiency Anemia K J Schulze and M L Dreyfuss	101
Megaloblastic Anemia J M Scott and P Browne	109
ANTIOXIDANTS	
Diet and Antioxidant Defense	117
Observational Studies I F F Benzie	13
Intervention Studies S Stanner	138
APPETITE	
Physiological and Neurobiological Aspects J C G Halford and J E Blundell	147
Psychobiological and Behavioral Aspects R J Stubbs, S Whybrow and J E Blundell	15
ARTHRITIS L A Coleman and R Roubenoff	163
ASCORBIC ACID	
Physiology, Dietary Sources and Requirements D A Bender	169
Deficiency States C J Bates	176
ATHEROSCLEROSIS see CHOLESTEROL: Sources, Absorption, Function and Metabolism. CORONARY	
HEART DISEASE: Prevention	

B	
B VITAMINS see COBALAMINS, NIACIN, PANTOTHENIC ACID, RIBOFLAVIN, THIAMIN; Physiology;	
Beriberi. VITAMIN B <sub>6</sub>	
BACTERIA see INFECTION: Nutritional Interactions; Nutritional Management in Adults	
BASES see ELECTROLYTES: Acid-Base Balance	
BEER see ALCOHOL: Absorption, Metabolism and Physiological Effects; Disease Risk and Beneficial Effects;	
Effects of Consumption on Diet and Nutritional Status	
BEHAVIOR E L Gibson and M W Green	183
BERIBERI see THIAMIN; Beriberi	
BEVERAGES see ALCOHOL: Absorption, Metabolism and Physiological Effects; Disease Risk and Beneficial	
Effects; Effects of Consumption on Diet and Nutritional Status. TEA	
BIOAVAILABILITY R J Wood	195
BIOTIN D M Mock	201
BLOOD LIPIDS/FATS see HYPERLIPIDEMIA: Overview. LIPOPROTEINS	
BLOOD PRESSURE see HYPERTENSION: Etiology	
BODY COMPOSITION D Gallagher and S Chung	210
BONE B M Thomson	220
BRAIN AND NERVOUS SYSTEM J D Femstrom and M H Femstrom	225
BREAST FEEDING C K Lutter	232
BURNS PATIENTS S A HIII	238
С	
CAFFEINE M.J. Arnaud	247
CALCIUM L H Allen and J E Kerstetter	253
CALORIES see ENERGY: Balance; Requirements. ENERGY EXPENDITURE: Indirect Calorimetry; Doubly	
Labeled Water	
CANCER	
Epidemiology and Associations Between Diet and Cancer G A Colditz	260
Epidemiology of Gastrointestinal Cancers Other Than Colorectal Cancers H-Y Huang	266
Epidemiology of Lung Cancer A J Alberg and J M Samet	272
Dietary Management C Shaw	284
Effects on Nutritional Status C Shaw	289
Carcinogenic Substances in Food D Anderson and J C Phillips	295
CARBOHYDRATES	
Chemistry and Classification C L Stylianopoulos	303
Regulation of Metabolism C L Stylianopoulos	309
Requirements and Dietary Importance C L Stylianopoulos	316
Resistant Starch and Oligosaccharides A Laurentin and C A Edwards	322
CARCINOGENS see CANCER: Carcinogenic Substances in Food	
CAROTENOIDS	
Chemistry, Sources and Physiology B K Ishida and G E Bartley	330
Epidemiology of Health Effects S A Tanumihardjo and Z Yang	339
CEREAL GRAINS R W Welch	346
CHEESE see DAIRY PRODUCTS	
CHILDREN	
Nutritional Requirements M Lawson	357
Nutritional Problems E M E Poskitt	370

CHOLECALCIFEROL see VITAMIN D: Physiology, Dietary Sources and Requirements; Rickets and	
Osteomalacia CHOLESTEROL	
	076
Sources, Absorption, Function and Metabolism D J McNamara	379
Factors Determining Blood Levels S M Grundy	385
CHOLINE AND PHOSPHATIDYLCHOLINE X Zhu and S H Zeisel	392
CHROMIUM R A Anderson	396
COBALAMINS R Green	401
CELIAC DISEASE V Nehra, E Marietta and J Murray	407
COFACTORS	2222
Inorganic E D Harris	418
Organic E D Harris	427
COFFEE see CAFFEINE	
COLON A Markey	(ADD
Structure and Function A Maqbool	439
Disorders A Maqbool  Notational Management of Disorders D.M.Klurfold	
Nutritional Management of Disorders D M Klurfeld	460
COMPLEMENTARY FEEDING K G Dewey	465
COPPER X Xu, S Pin, J Shedlock and Z L Harris	471
CORONARY HEART DISEASE	476
Hemostatic Factors W Gilmore	- 555
Lipid Theory D Kritchevsky	482
Prevention K Srinath Reddy	487
CYSTIC FIBROSIS J Downsett and O Tully	494
CYTOKINES R F Grimble	501
D	
DAIRY PRODUCTS J Buttriss	511
DEHYDRATION A W Subudhi, E W Askew and M J Luetkemeier	518
DENTAL DISEASE R C Cottrell	527
DIABETES MELLITUS	
Etiology and Epidemiology J Sudagani and G A Hitman	535
Classification and Chemical Pathology K C McCowen and R J Smith	543
Dietary Management C D Saudek and S H Oh	551
DIARRHEAL DISEASES A Baqui, R Heinzen, M Santosham and R Black	565
DIETARY FIBER	
Physiological Effects and Effects on Absorption IT Johnson	572
Potential Role in Etiology of Disease D L Topping and L Cobiac	578
Role in Nutritional Management of Disease A R Leeds	586
VOLUME 2	
DIETARY GUIDELINES, INTERNATIONAL PERSPECTIVES B Schneeman	1
DIETARY INTAKE MEASUREMENT	9.0
Methodology A A Welch	7
Validation M Nelson	16
DIETARY SURVEYS K.L. Tucker	27

DIETETICS P A Judd  DIGESTIBILITY see BIOAVAILABILITY	32
DRUG-NUTRIENT INTERACTIONS K G Conner	38
E	
EARLY ORIGINS OF DISEASE	
Fetal A J Buckley and S E Ozanne	51
Non-Fetal L S Adair	59
EATING BEHAVIOR see MEAL SIZE AND FREQUENCY EATING DISORDERS	
Anorexia Nervosa A R Rolla	66
Bulimia Nervosa A J Hill and S F L Kirk	74
	80
Binge Eating M D Marcus, M A Kalarchian and M D Levine	10000
EGGS D J McNamara and H S Thesmar	86
EICOSANOIDS see PROSTAGLANDINS AND LEUKOTRIENES	
ELECTROLYTES	******
Acid-Base Balance A G Jardine and P B Mark	93
Water–Electrolyte Balance S M Shirreffs and R J Maughan	100
ENERGY	08868
Metabolism S Cox	106
Balance Y Schutz	115
Requirements WPT James	125
Adaptation A G Dulloo and J Jacquet	131
ENERGY EXPENDITURE	400
Indirect Calorimetry A Raman and D A Schoeller	139
Doubly Labeled Water W A Coward	145
EXERCISE	343
Beneficial Effects C Boreham and M H Murphy	154
Diet and Exercise R J Maughan	162
F	
FAMINE K P West Jr	169
FAT-SOLUBLE VITAMINS see VITAMIN A: Biochemistry and Physiological Role. VITAMIN D: Physiology,	
Dietary Sources and Requirements; Rickets and Osteomalacia. VITAMIN E: Metabolism and	
Requirements, VITAMIN K	
FAT STORES see ADIPOSE TISSUE	
FATS see FATTY ACIDS: Metabolism; Monounsaturated; Omega-3 Polyunsaturated; Omega-6	
Polyunsaturated; Saturated; Trans Fatty Acids. LIPIDS: Chemistry and Classification; Composition and	
Role of Phospholipids	
FATS AND OILS A H Lichtenstein	177
FATTY ACIDS	
Metabolism P A Watkins	186
Monounsaturated P Kirk	198
Omega-3 Polyunsaturated A P Simopoulos	205
Omega-6 Polyunsaturated J M Hodgson, T A Mori and M L Wahlqvist	219
Saturated R P Mensink and E H M Temme	225
Trans Fatty Acids M J Sadler	230

CONTENTS	xxxi
FERTILITY R E Frisch	237
FETAL ORIGINS OF DISEASE see EARLY ORIGINS OF DISEASE: Fetal: Non-Fetal	251
FIBER see DIETARY FIBER: Physiological Effects and Effects on Absorption; Potential Role in Etiology of	
Disease; Role in Nutritional Management of Disease	
FISH A Ariño, J A Beltrán, A Herrera and P Roncalés	247
FLAVONOIDS see PHYTOCHEMICALS: Classification and Occurrence; Epidemiological Factors	EHY
FOLATE see FOLIC ACID	
FOLIC ACID J McPartlin	257
FOOD ALLERGIES	20,
Etiology T J David	265
Diagnosis and Management T J David	270
FOOD CHOICE, INFLUENCING FACTORS A K Draper	277
FOOD COMPOSITION DATA S P Murphy	282
FOOD FOLKLORE J Dwyer and J Freitas	289
FOOD FORTIFICATION	200
Developed Countries R Nalubola	295
Developing Countries O Dary and J O Mora	302
FOOD INTAKE see DIETARY INTAKE MEASUREMENT: Methodology; Validation, DIETARY SURVEYS.	002
MEAL SIZE AND FREQUENCY	
FOOD INTOLERANCE T J David	309
FOOD SAFETY	377.5
Mycotoxins J D Groopman and T W Kensler	317
Pesticides M Saltmarsh	323
Bacterial Contamination N Noah	329
Other Contaminants C K Winter	340
Heavy Metals G L Klein	344
FORTIFICATION see FOOD FORTIFICATION: Developed Countries; Developing Countries	
FRUCTOSE N L Keim and P J Havel	351
FRUITS AND VEGETABLES A E Bender	356
FUNCTIONAL FOODS	
Health Effects and Clinical Applications L Galland	360
Regulatory Aspects H H Butchko and B J Petersen	366
TO BE THE SECOND SECTION OF THE PROPERTY OF THE SECOND SECTION OF THE SECOND SECTION OF THE SECOND S	
G	
GALACTOSE A Abi-Hanna and J M Saavedra	377
GALL BLADDER DISORDERS B Nejadnik and L Cheskin	384
GERIATRIC NUTRITION see OLDER PEOPLE: Physiological Changes; Nutritional Requirements;	00.1
Nutrition-Related Problems; Nutritional Management of Geriatric Patients	
GLUCOSE	
Chemistry and Dietary Sources D J A Jenkins, R de Souza, L S A Augustin and C W C Kendall	390
Metabolism and Maintenance of Blood Glucose Level V Marks	398
Glucose Tolerance B Ahrén	405
GLYCEMIC INDEX G Frost and A Dornhorst	413
GOITRE see IODINE: Deficiency Disorders	110
GOUT L A Coleman and R Roubenoff	419
GRAINS see CEREAL GRAINS	100000
GROWTH AND DEVELOPMENT, PHYSIOLOGICAL ASPECTS W W Hay Jr	423
500 NO 100 NO 10	27.1

GROWTH MONITORING T J Cole GUT FLORA see MICROBIOTA OF THE INTESTINE: Probiotics; Prebiotics	433
н	
HANDICAP	
Down's Syndrome M Collins and A Laverty	443
Prader–Willi Syndrome A O Scheimann	449
Cerebral Palsy J Krick and P Miller	452
HEART DISEASE see CORONARY HEART DISEASE: Hemostatic Factors; Lipid Theory; Prevention	
HEIGHT see NUTRITIONAL ASSESSMENT: Anthropometry	
HOMOCYSTEINE J W Miller	462
HUNGER J C G Halford, A J Hill and J E Blundell	469
HYPERACTIVITY M Wolraich	475
HYPERLIPIDEMIA	
Overview T R Trinick and E B Duly	479
Nutritional Management A H Lichtenstein	491
HYPERTENSION	
Etiology T Morgan and H Brunner	499
Dietary Factors   L J Appel	506
Nutritional Management C M Champagne	513
HYPOGLYCEMIA V Marks	523
VOLUME 3	
1	
IMMUNE SYSTEM see IMMUNITY: Physiological Aspects; Effects of Iron and Zinc IMMUNITY	
Physiological Aspects A T Borchers, C L Keen and M E Gershwin	1
Effects of Iron and Zinc C Doherty	7
INBORN ERRORS OF METABOLISM	
Classification and Biochemical Aspects D L Marsden	13
Nutritional Management of Phenylketonuria D L Marsden, F J Rohr and K C Costas	22
INFANTS	
Nutritional Requirements S A Atkinson	28
Feeding Problems R M Katz, L Schuberth and C S Gulotta	42
INFECTION	
Nutritional Interactions H Ghattas	47
Nutritional Management in Adults J A Tayek	54
INTESTINE see SMALL INTESTINE: Structure and Function; Disorders; MICROBIOTA OF THE INTESTINE: Probiotics; Prebiotics	
IODINE	
Physiology, Dietary Sources and Requirements R Houston	66
Deficiency Disorders B S Hetzel	74
IRON JR Hunt	82
ISCHEMIC HEART DISEASE see CORONARY HEART DISEASE: Lipid Theory	

K	
KESHAN DISEASE see SELENIUM	
KETOSIS D H Williamson	91
L	
LACTATION	
Physiology J L McManaman and M C Neville	98
Dietary Requirements N M F Trugo and C M Donangelo	106
LACTOSE INTOLERANCE D M Paige	113
LEGUMES M A Grusak LIPIDS	120
Chemistry and Classification J L Dupont	126
Composition and Role of Phospholipids A D Postle	132
LIPOPROTEINS J M Ordovas	143
LIVER DISORDERS J Hampsey and K B Schwarz	150
LOW BIRTHWEIGHT AND PRETERM INFANTS	(5021)
Causes, Prevalence and Prevention M Merialdi and M de Onis	161
Nutritional Management J M Cox	168
LUNG DISEASES A MacDonald  LYCOPENES AND RELATED COMPOUNDS C J Bates	175
LYCOPENES AND RELATED COMPOUNDS C 3 Bales	104
M	
MAGNESIUM C Feillet-Coudray and Y Rayssiguler	191
MALABSORPTION SYNDROMES P M Tsai and C Duggan	196
MALNUTRITION	
Primary, Causes Epidemiology and Prevention A Briend and P Nestel	203
Secondary, Diagnosis and Management N Solomons	212
MANGANESE C L Keen, J L Ensunsa, B Lönnerdal and S Zidenberg-Cherr	217
MEAL SIZE AND FREQUENCY F E Leahy	225
MEAT, POULTRY AND MEAT PRODUCTS P A Lofgren	230
MENKES SYNDROME see COPPER	
MICROBIOTA OF THE INTESTINE	007
Prebiotics J M Saavedra and N Moore  Probiotics M Gueimonde and S Salminen	237
MILK see DAIRY PRODUCTS	244
MINERALS see CALCIUM, MAGNESIUM, PHOSPHORUS, POTASSIUM, SODIUM: Physiology	
MOLYBDENUM see ULTRATRACE ELEMENTS	
MONOSATURATED FAT see FATTY ACIDS: Monounsaturated	
MYCOTOXINS see FOOD SAFETY: Mycotoxins	
N	
NIACIN C J Bates	253
NITROGEN see AMINO ACIDS: Chemistry and Classification; Metabolism. PROTEIN: Digestion and Bioavailability; Quality and Sources; Requirements and Role in Diet; Deficiency	
NUCLEIC ACIDS E A Carrey and H A Simmonds	260

NUTRIENT-GENE INTERACTIONS	
Molecular Aspects C D Berdanier and H C Freake	269
Health Implications C D Berdanier and H C Freake	276
NUTRIENT REQUIREMENTS, INTERNATIONAL PERSPECTIVES A A Yates	282
NUTRITION POLICIES IN DEVELOPING AND DEVELOPED COUNTRIES C Geissler	293
NUTRITION TRANSITION, DIET CHANGE AND ITS IMPLICATIONS B M Popkin	301
NUTRITIONAL ASSESSMENT	
Anthropometry J Eaton-Evans	311
Biochemical Indices F Fidanza	318
Clinical Examination B Caballero	329
NUTRITIONAL SUPPORT	
In the Home Setting M Elia and R J Stratton	332
Adults, Enteral K N Jeejeebhoy	342
Adults, Parenteral J Binkley, S Daniell and G L Jensen	349
Infants and Children, Parenteral S Collier and C Lo	357
NUTRITIONAL SURVEILLANCE	
Developed Countries N R Sahyoun	363
Developing Countries L M Neufeld and L Tolentino	371
NUTS AND SEEDS J Gray	381
0	
OBESITY	
Definition, Etiology and Assessment A Pietrobelli	389
Fat Distribution J Stevens and K P Truesdale	392
Childhood Obesity E M E Poskitt	399
Complications A Ahmed and R L Atkinson	406
Prevention T P Gill	413
Treatment E C Uchegbu and P G Kopelman	421
OILS see FATS AND OILS	
OLDER PEOPLE	
Physiological Changes N Solomons	431
Nutritional Requirements N Solomons	437
Nutrition-Related Problems C P G M de Groot and W A van Staveren	444
Nutritional Management of Geriatric Patients	449
OSTEOMALACIA see VITAMIN D: Rickets and Osteomalacia	
OSTEOPOROSIS K O O'Brien	460
OXIDANT DAMAGE see ANTIOXIDANTS: Observational Studies; Intervention Studies	
P	
PANTOTHENIC ACID C J Bates	467
PARASITISM P G Lunn	472
PATHOGENS see INFECTION: Nutritional Interactions; Nutritional Management in Adults	
PELLAGRA C J Bates	481
PESTICIDES see FOOD SAFETY: Pesticides	401
PHENYLKETONURIA see INBORN ERRORS OF METABOLISM: Nutritional Management of	Phenylketonuria
PHOSPHATE see SMALL INTESTINE: Structure and Function	in i
PHOSPHORUS L.I.B. Anderson	486

SALT see SODIUM: Physiology; Salt Intake and Health

SATIETY see APPETITE: Physiological and Neurobiological Aspects

SATURATED FAT see FATTY ACIDS: Saturated	
SEASONALITY F Branca and P D'Acapito	109
SEEDS see NUTS AND SEEDS	
SELENIUM C J Bates	118
SENESCENCE see AGING	
SKINFOLD THICKNESS see NUTRITIONAL ASSESSMENT: Anthropometry	
SMALL INTESTINE	
Structure and Function D Rumsey	126
Disorders R D'Souza and J Powell-Tuck	133
SOCIO-ECONOMIC STATUS E Dowler	140
SODIUM	
Physiology A R Michell	150
Salt Intake and Health C P Sanchez-Castillo and W P T James	154
SODIUM CHLORIDE see SODIUM: Salt Intake and Health	
SPIRITS see ALCOHOL: Absorption, Metabolism and Physiological Effects; Disease Risk and Beneficial	
Effects; Effects of Consumption on Diet and Nutritional Status	
SPORTS NUTRITION R J Maughan	167
STARCH see CARBOHYDRATES: Chemistry and Classification; Regulation of Metabolism; Requirements	
and Dietary Importance; Resistant Starch and Oligosaccharides	
STARVATION AND FASTING J E Bines and R G Heine	173
STOMACH	
Structure and Function J P Pearson and I A Brownlee	180
Disorders J A Solon	190
STROKE, NUTRITIONAL MANAGEMENT S McLaren	196
SUCROSE	
Nutritional Role, Absorption and Metabolism J Brand-Miller	204
Dietary Sucrose and Disease B Caballero	212
SUGAR see CARBOHYDRATES: Chemistry and Classification; Regulation of Metabolism; Requirements and	
Dietary Importance; GALACTOSE. GLUCOSE: Chemistry and Dietary Sources; Metabolism and	
Maintenance of Blood Glucose Level; Glucose Tolerance. SUCROSE: Nutritional Role, Absorption and	
Metabolism; Dietary Sucrose and Disease	
SUPPLEMENTATION	
Dietary Supplements S S Percival	214
Role of Micronutrient Supplementation R D W Klemm	220
Developing Countries R Shrimpton	227
Developed Countries M F Picciano and S S McDonald	233
SURGERY	
Perioperative Feeding E Kelly	241
Long-term Nutritional Management E Lin and T R Ziegler	246
Т	
TEA D J Baer and S C Chen	257
TEETH see DENTAL DISEASE	
THIAMIN	
Physiology D I Thurnham	263
Beriberi D I Thurnham	269

	CONTENTS	xxxvii
THIRST J Leiper		278
TOCOPHEROL see VITAMIN E: Metabolism and Requirements; Physiology and Health Effects		210
TRACE ELEMENTS see CHROMIUM. COPPER. IMMUNITY: Effects of Iron and Zinc. IODINE: Physiology, Dietary Sources and Requirements. IRON. MANGANESE. SELENIUM. ZINC:		
Physiology		
TRANS FATTY ACIDS see FATTY ACIDS: Trans Fatty Acids		
TUBERCULOSIS		
Nutrition and Susceptibility J P Cegielski and D N McMurray		287
Nutritional Management J P Cegielski and L Demeshlaira		294
TUMOR see CANCER: Epidemiology and Associations Between Diet and Cancer; Epidemiology	of	
Gastrointestinal Cancers Other Than Colorectal Cancers; Epidemiology of Lung Cancer		
U		000
ULTRATRACE ELEMENTS F Nielsen		299
UNITED NATIONS CHILDREN'S FUND J P Greaves and R Shrimpton		311
URBAN NUTRITION N Solomons		317
v		
VEGAN DIETS see VEGETARIAN DIETS		
VEGETABLES see FRUITS AND VEGETABLES		
VEGETARIAN DIETS J Dwyer		323
VITAMIN A		
Physiology A C Ross		329
Biochemistry and Physiological Role J L Napoli		339
Deficiency and Interventions KP West Jr		348
VITAMIN B, see THIAMIN: Physiology; Beriberi		
VITAMIN B <sub>2</sub> see RIBOFLAVIN		
VITAMIN B <sub>6</sub> D A Bender		359
VITAMIN B <sub>12</sub> see COBALAMINS		
VITAMIN C see ASCORBIC ACID: Physiology, Dietary Sources and Requirements; Deficiency S	States	
VITAMIN D		
Physiology, Dietary Sources and Requirements M F Holick		368
Rickets and Osteomalacia J J B Anderson		378
VITAMIN E		
Metabolism and Requirements M G Traber		383
Physiology and Health Effects P A Morrissey and M Kiely		389
VITAMIN K C J Bates		398
W		
WATER see THIRST		
WEIGHT MANAGEMENT		10000
Approaches N Finer		407
Weight Maintenance H A Raynor and R R Wing		413
Weight Cycling L Lissner		421
WHOLE GRAINS R Lang and S A Jebb		427

WILSON'S DISEASE see COPPER

INDEX

WINE see ALCOHOL; Absorption, Metabolism and Physiological Effects; Disease Risk a Effects of Consumption on Diet and Nutritional Status	and Beneficial Effects;
WORLD HEALTH ORGANIZATION J Akré	43
Y	
YOGURT see DAIRY PRODUCTS. FUNCTIONAL FOODS: Health Effects and Clinical MICROBIOTA OF THE INTESTINE: Probiotics; Preblotics	Applications;
z	
ZINC	
Physiology H C Freake	447
Deficiency in Developing Countries, Intervention Studies C Hotz	454

463